Nebivolol, third-generation β-blocker, may activate β3-adrenergic receptor (AR), which has been emerged as a novel and potential therapeutic targets for
cardiovascular diseases. However, it is not known whether
nebivolol administration plays a cardioprotective effect against
myocardial infarction (MI) injury. Therefore, the present study was designed to clarify the effects of
nebivolol on MI injury and to elucidate the underlying mechanism. MI model was constructed by left anterior descending (LAD) artery
ligation.
Nebivolol, β3-AR antagonist (
SR59230A), Nitro-
L-arginine methylester (
L-NAME) or vehicle was administered for 4 weeks after MI operation. Cardiac function was monitored by echocardiography. Moreover, the
fibrosis and the apoptosis of myocardium were assessed by Masson's
trichrome stain and TUNEL assay respectively 4 weeks after MI.
Nebivolol administration reduced
scar area by 68% compared with MI group (p<0.05). Meanwhile,
nebivolol also decreased the myocardial apoptosis and improved the heart function after MI (p<0.05 vs. MI). These effects were associated with increased β3-AR expression. Moreover,
nebivolol treatment significantly increased the phosphorylation of endothelial NOS (eNOS) and the expression of neuronal NOS (nNOS). Conversely, the cardiac protective effects of
nebivolol were abolished by SR and
L-NAME. These results indicate that
nebivolol protects against MI injury. Furthermore, the cardioprotective effects of
nebivolol may be mediated by β3-AR-eNOS/nNOS pathway.